Storing blood and protein samples from cancer patients
Official title: Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic
Run by Maastricht Radiation Oncology · NCT01084785 · Data updated 2026-11-12
This study is collecting blood samples from lung cancer patients to see how their DNA and proteins relate to their treatment outcomes and survival.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Maastricht Radiation Oncology Academic / other |
| Locations | 1 site (Maastricht, Limburg) |
| Status | Recruiting |
| Started | January 1, 2003 |
| Main results expected | May 1, 2026 |
| Study ends | May 1, 2026 |
| Registry record updated | May 13, 2025 |
| Trial ID | NCT01084785 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with lung cancer who are able to comply with follow-up requirements.
✕Probably not a fit
Patients who are not diagnosed with cancer or those unable to comply with follow-up will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to analyze the relationship between DNA and protein profiles in cancer patients and various important clinical endpoints, such as overall survival and treatment side effects. By collecting and storing blood samples from patients with lung cancer at the MAASTRO clinic, researchers will conduct future DNA and protein analyses to better understand how genetic and environmental factors influence cancer outcomes. The study seeks to address gaps in previous research by utilizing a larger and more diverse patient population to establish clearer correlations between biological markers and clinical results.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of cancer prognosis and treatment side effects, ultimately enhancing patient care.
How similar studies have gone: While similar studies have been conducted, this approach focuses on a specific cancer type and aims to establish stronger correlations through a larger patient cohort, making it a novel effort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * cancer Exclusion Criteria: * not able to comply with follow-up
Where it's running
-
Maastricht Radiation Oncology
Maastricht, Limburg, Netherlands Recruiting
Study contacts
- Principal investigator: Dirk De Ruysscher, Prof PHD — Ccmo
- Study coordinator: Philippe Lambin, Prof PHD
- Email: philippe.lambin@maastro.nl
- Phone: 31 (0) 088 44 55 666
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MAASTRO HDR rectal applicator registry
This registry collects data from adults with rectal cancer treated with the MAASTRO high-dose-rate (HDR) rectal applicator to see if different dose patterns relate to better tumor responses.
-
Mini-tumors to guide treatment for aggressive prostate cancer
We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.
-
Tracking treatment delivery during brachytherapy
This study is testing a new way to track and confirm that the right dose of brachytherapy is delivered accurately to patients during their treatment.
-
Developing organoids from breast cancer tissue
This study is trying to create mini versions of breast cancer tumors from patient samples to see how they can help doctors understand the disease better and choose the best treatments for each person.
-
Defining target volume for radiation boosting in rectal cancer
This study is trying to understand how rectal cancer spreads in order to improve radiation treatment for patients who still have cancer after their initial therapy.
-
Creating a living tissue bank from glioma tumors
This study is trying to create mini versions of glioma tumors from patients to see how they behave and how different treatments might work better for people with glioma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.